Recent News

• 05.13.2026 - Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026
• 04.02.2026 - Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System
• 03.26.2026 - Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025
• 03.10.2026 - Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing
• 03.05.2026 - Dermata Opens a New Chapter with the Release of Tome Skincare

Recent Filings

• 04.22.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.17.2026 - DEF 14A Other definitive proxy statements
• 04.17.2026 - ARS Annual Report to Security Holders
• 04.17.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.07.2026 - PRE 14A Other preliminary proxy statements
• 03.26.2026 - EX-99.1 EX-99.1
• 03.26.2026 - 8-K Current report
• 03.26.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.25.2026 - 8-K Current report